|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
For in vivo validation we selected CSNK1e, a kinase whose expression correlated with MYCN amplification in neuroblastoma (an established MYC-driven cancer).
|
22623531 |
2012 |
|
Primary malignant neoplasm
|
0.050 |
AlteredExpression
|
group |
BEFREE |
For in vivo validation we selected CSNK1e, a kinase whose expression correlated with MYCN amplification in neuroblastoma (an established MYC-driven cancer).
|
22623531 |
2012 |
|
Malignant neoplasm of breast
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here we identify CSNK1E, the gene encoding casein kinase 1 epsilon (CK1epsilon) as required specifically for the proliferation of breast cancer cells with activated beta-catenin and confirm its role as a positive regulator of beta-catenin-driven transcription.
|
20126544 |
2010 |
|
Breast Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Here we identify CSNK1E, the gene encoding casein kinase 1 epsilon (CK1epsilon) as required specifically for the proliferation of breast cancer cells with activated beta-catenin and confirm its role as a positive regulator of beta-catenin-driven transcription.
|
20126544 |
2010 |
|
West Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we performed WES on four trios with West syndrome and identified three loss-of-function DNMs in both CSNK1E (c.885+1G>A) and STXBP1 (splicing, c.1111-2A>G; nonsense, p.(Y519X)).
|
30488659 |
2019 |
|
Bipolar Disorder
|
0.360 |
GeneticVariation
|
disease |
BEFREE |
However, a 4-locus CSNK1E haplotype encompassing the rs1534891 SNP (Z-score=2.685, permuted p=0.0076) and a 3-locus haplotype in ARNTL (Z-score=3.269, permuted p=0.0011) showed a significant association with BD.
|
26283580 |
2015 |
|
Malignant neoplasm of mouth
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Impact of Polymorphisms in Casein Kinase 1 Epsilon and Environmental Factors in Oral Cancer Susceptibility.
|
31602258 |
2019 |
|
Lip and Oral Cavity Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Impact of Polymorphisms in Casein Kinase 1 Epsilon and Environmental Factors in Oral Cancer Susceptibility.
|
31602258 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, we also observed that REGγ depletion activated Hippo signaling pathway via stabilizing CK1ε in RCC, indicating the cross-talk between REGγ/CK1ε axis and Hippo pathway during RCC development.
|
29795381 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Importantly, we also observed that REGγ depletion activated Hippo signaling pathway via stabilizing CK1ε in RCC, indicating the cross-talk between REGγ/CK1ε axis and Hippo pathway during RCC development.
|
29795381 |
2018 |
|
Kidney Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In kidney tumor tissue, we found down-regulation of PER2 (median=0.658, Q1-Q3=0.562-0.744, P<0.01), TIMELESS (median=0.705, Q1-Q3=0.299-1.330, P=0.04) and TIPIN (median=0.556, Q1-Q3=0.385-1.945, P=0.01), up-regulation of SERPINE1 (median=1.628, Q1-Q3=0.339-4.071, P=0.04), whereas the expression of ARNTL2 (median=0.605, Q1-Q3=0.318-1.738, P=0.74) and CSNK1E (median=0.927, Q1-Q3=0.612-2.321, P=0.33) did not differ.
|
22436651 |
2012 |
|
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, our findings show that high expression of CK1ε is positively associated with the Dukes staging and depth of invasion in CRC patients, and knockdown of CK1ε suppresses the growth and invasion of CRC cells through inhibition of the wnt/β-catenin signaling, suggesting that CK1ε may serve as a promising therapeutic target for the treatment of CRC.
|
26122218 |
2015 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings show that high expression of CK1ε is positively associated with the Dukes staging and depth of invasion in CRC patients, and knockdown of CK1ε suppresses the growth and invasion of CRC cells through inhibition of the wnt/β-catenin signaling, suggesting that CK1ε may serve as a promising therapeutic target for the treatment of CRC.
|
26122218 |
2015 |
|
Mood Disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
In MDR analysis, the combination of TIMELESS rs4630333 and CSNK1E rs135745 exhibited the most significant association with mood disorders in the two-locus model.
|
31323592 |
2019 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our previous work, we identified casein kinase 1 ε (CK1ε, also known as CSNK1E) as a potential survival factor in glioblastoma.
|
30206363 |
2018 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our previous work, we identified casein kinase 1 ε (CK1ε, also known as CSNK1E) as a potential survival factor in glioblastoma.
|
30206363 |
2018 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our previous work, we identified casein kinase 1 ε (CK1ε, also known as CSNK1E) as a potential survival factor in glioblastoma.
|
30206363 |
2018 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
In our previous work, we identified casein kinase 1 ε (CK1ε, also known as CSNK1E) as a potential survival factor in glioblastoma.
|
30206363 |
2018 |
|
Malignant neoplasm of breast
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In silico modeling and in vivo data showed that autophosphorylation at Thr 44, a site adjacent to the breast cancer point mutations in the N-terminal lobe of human CK1epsilon, is involved in positive regulation of the CK1epsilon activity.
|
20507565 |
2010 |
|
Breast Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In silico modeling and in vivo data showed that autophosphorylation at Thr 44, a site adjacent to the breast cancer point mutations in the N-terminal lobe of human CK1epsilon, is involved in positive regulation of the CK1epsilon activity.
|
20507565 |
2010 |
|
Malignant neoplasm of breast
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In women with three consecutive night shifts, a reduced risk of breast cancer was associated with carriage of variant alleles of SNPs in CLOCK (rs3749474), BMAL1 (rs2278749), BMAL2 (rs2306074), CSNK1E (rs5757037), NPAS2 (rs17024926), ROR-b (rs3903529, rs3750420), MTNR1A (rs131113549) and PER3 (rs1012477).
|
23822714 |
2013 |
|
Breast Carcinoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In women with three consecutive night shifts, a reduced risk of breast cancer was associated with carriage of variant alleles of SNPs in CLOCK (rs3749474), BMAL1 (rs2278749), BMAL2 (rs2306074), CSNK1E (rs5757037), NPAS2 (rs17024926), ROR-b (rs3903529, rs3750420), MTNR1A (rs131113549) and PER3 (rs1012477).
|
23822714 |
2013 |
|
Sleep Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Indeed, Casein kinase I epsilon (CKIvarepsilon) promotes reversible phosphorylation of PER proteins, and a deficiency in this phosphorylation has been implicated in human sleep disorders.
|
18571740 |
2008 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis found high expression of CK1ε to be associated with a statistically significant higher disease-free survival (DFS) in BC patients with wild-type p53 (Hazard ratio [HR] = 0.33; 95% CI, 0.12-0.91; P = 0.018) or poor histological differentiation ([HR] = 0.34; 95% CI, 0.12-0.94; P = 0.039) or in those without adjuvant chemotherapy ([HR] = 0.11; 95% CI, 0.01-0.97; P = 0.006).
|
26327509 |
2015 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Multivariate analysis found high expression of CK1ε to be associated with a statistically significant higher disease-free survival (DFS) in BC patients with wild-type p53 (Hazard ratio [HR] = 0.33; 95% CI, 0.12-0.91; P = 0.018) or poor histological differentiation ([HR] = 0.34; 95% CI, 0.12-0.94; P = 0.039) or in those without adjuvant chemotherapy ([HR] = 0.11; 95% CI, 0.01-0.97; P = 0.006).
|
26327509 |
2015 |